These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 19550054)

  • 1. Clinical information in drug package inserts in India.
    Shivkar YM
    J Postgrad Med; 2009; 55(2):104-7. PubMed ID: 19550054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Improvement of package insert CYP information for prescription drugs marketed in Japan].
    Hirata-Koizumi M; Saito M; Urano T; Miyake S; Hasegawa R
    Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2005; (123):12-8. PubMed ID: 16541745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of German package inserts.
    Fuchs J; Hippius M; Schaefer M
    Int J Clin Pharmacol Ther; 2006 Jan; 44(1):8-13. PubMed ID: 16425965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A literature search on pharmacokinetic drug interactions of statins and analysis of how such interactions are reflected in package inserts in Japan.
    Saito M; Hirata-Koizumi M; Urano T; Miyake S; Hasegawa R
    J Clin Pharm Ther; 2005 Feb; 30(1):21-37. PubMed ID: 15659001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Use of antidepressants during breastfeeding: evaluating drug package inserts conformity with science-based bibliographical sources].
    Pizzol TDSD; Moraes CG; Diello MV; Campos PM; Pletsch JT; Giugliani C
    Cad Saude Publica; 2019 Feb; 35(2):e00041018. PubMed ID: 30785486
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of prescribing information for generic drugs manufactured in the Middle East and marketed in Saudi Arabia.
    Gebran N; Al Haidari K
    Ann Saudi Med; 2006; 26(3):192-9. PubMed ID: 16861873
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Critical Evaluation of Pharmacogenetic Information in Package Inserts for Selected Drugs Marketed in India and Its Comparison With US FDA-Approved Package Inserts.
    Pai SA; Kshirsagar N
    J Clin Pharmacol; 2016 Oct; 56(10):1232-42. PubMed ID: 26873003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Drug package inserts--varying information for the same medicines].
    Storflor JG; Pettersen LC; Slørdal L; Spigset O
    Tidsskr Nor Laegeforen; 2013 May; 133(9):955-9. PubMed ID: 23652143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Information on marketed drugs for doctors and patients. Experience in six European countries.
    Brown P; Charlish P; Brazier H; Butterfield M
    Int J Technol Assess Health Care; 1995; 11(3):410-6. PubMed ID: 7591543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Drug package inserts and the adequacy of patient's drug information].
    da Silva T; Dal-Pizzol F; Bello CM; Mengue SS; Schenkel EP
    Rev Saude Publica; 2000 Apr; 34(2):184-9. PubMed ID: 10881155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conformity of package inserts information to regulatory requirements among selected branded and generic medicinal products circulating on the East African market.
    Sillo HB; Masota NE; Kisoma S; Rago L; Mgoyela V; Kaale EA
    PLoS One; 2018; 13(5):e0197490. PubMed ID: 29787579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A study of package inserts in southern India.
    Ramdas D; Chakraborty A; Hs S; Faizan S; Kumar V P; Bn S
    J Clin Diagn Res; 2013 Nov; 7(11):2475-7. PubMed ID: 24392376
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ontological Organization and Bioinformatic Analysis of Adverse Drug Reactions From Package Inserts: Development and Usability Study.
    Li X; Lin X; Ren H; Guo J
    J Med Internet Res; 2020 Jul; 22(7):e20443. PubMed ID: 32706718
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient information leaflets--helpful guidance or a source of confusion?
    Bjerrum L; Foged A
    Pharmacoepidemiol Drug Saf; 2003; 12(1):55-9. PubMed ID: 12616848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prescribing information in 26 countries: a comparative study.
    Reggi V; Balocco-Mattavelli R; Bonati M; Breton I; Figueras A; Jambert E; Kopp C; Montane E; Rägo L; Rocchi F;
    Eur J Clin Pharmacol; 2003 Aug; 59(4):263-70. PubMed ID: 12759794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short communication: a study on the packaging information of essential drug products used at Union and Thana health complex level in Bangladesh.
    Amran S; Ahmed M; Shaheen SM; Morshed SN; Khandakar J; Rahman M; Rahman M; Hossain A
    Pak J Pharm Sci; 2007 Oct; 20(4):327-32. PubMed ID: 17604258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survey of safety and efficacy information in drug inserts for topical prescription medications.
    Zaghi D; Maibach HI
    Am J Clin Dermatol; 2007; 8(1):43-6. PubMed ID: 17298106
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Excessive medical information increase in package inserts.
    Fuchs J; Werner S; Scheunpflug C; Götze EA; Elstermann K; Scheffel K; Domnowski A; Peter G; Hertzsch C; Hippius M
    Int J Clin Pharmacol Ther; 2010 Dec; 48(12):781-90. PubMed ID: 21084033
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Patient-oriented package inserts for drugs. Historical overview and current status].
    Van Haecht CH; Vander Stichele R; Bogaert M
    Arch Belg; 1989; 47(5-6):230-55. PubMed ID: 2700065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Information regarding adverse drug effects and treatment indications ("package inserts") exemplified by cervistatin (Lipobay)].
    Braun RN; Halhuber MJ; Hitzenberger G
    Wien Med Wochenschr; 2003; 153(3-4):80-2. PubMed ID: 12658968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.